ArticleFrontiers in oncology2026
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objectives: In recent decades, many studies have examined the anticancer effects of parasites, but little attention has focused on enhancing these effects through nanotechnology, leaving a significant knowledge gap. Therefore, this study aims to enhance the Methods: This study used the colon tumor 26 (CT26) and Human foreskin fibroblast-3 (HFF-3) cell lines. Cells were treated with free or nanocapsulated AgB at 0.25, 0.5, and 1.0 mg/mL for 24, 48, and 72 h. MTT assay was used to evaluate cell viability, and Annexin V/PI staining was performed to assess apoptosis. Results: The mean nanocapsule size was 180.35 nm, and the Polydispersity Index (PDI) was 0.2600. Scanning electron microscopy (SEM) confirmed that the nanocapsules were spherical. Cytotoxicity against CT26 cells increased with both concentration and incubation time for free and nanocapsulated AgB. Nanocapsulated AgB consistently showed higher cytotoxicity than free AgB at matched nominal formulation concentrations and time points. At 72 h, 1.0 mg/mL nanocapsulated AgB showed the highest cytotoxicity (28.6 ± 0.6%), followed by free AgB at the same concentration (18.7 ± 0.5%). In HFF3 cells, the maximum cytotoxicity was observed at 72 h with 1.0 mg/mL free AgB (4.7 ± 0.2%) and nanocapsulated AgB (3.7 ± 0.1%), which were lower than the corresponding values in CT26 cells. Conclusions: In conclusion, the AgB-loaded nanoformulation exhibited greater
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.